Ujawnienia niefinansowe w obszarze działalności badawczo-rozwojowej : praktyki europejskich spółek biofarmaceutycznych

• Autorzy: Joanna Dyczkowska

Warianty tytułu

Non-financial disclosures in the research and development activity. Practices of European biopharmaceutical companies

• Języki publikacji: PL

Abstrakty

EN

With the emergence of a knowledge-based economy, the approach to traditional production factors, including land, capital and labour, which played an important role in the industrial economy, has changed. The growth of enterprises was determined by a smooth combination of expressed experience, values, appropriate selected information and expert insight into a given issue, i.e. knowledge [Davenport, Prusak 1998, p. 5]. This change influenced the approach to resource management, putting the importance of intellectual capital at the forefront as a key resource of human, organizational and relational character. From the end of World War II until the 1980s, pharmaceutical industry experienced a real boom that was possible thanks to the public support of research related to health care, which resulted in effective organizational procedures in the field of drug discovery and development and their commercialisation, as well as improvement of screening programs. Large pharmaceutical companies constituted the oligopolistic core of the market and were doing quite well in the "welfare states" with the national healthcare systems present in most European countries, which offered an organized and publicly available drug market [Orsenigo et al. 2006]. At the end of the 20th century, the approach to innovation changed with the development of molecular biology and new technologies. The role of scientific knowledge increased both at the stage of discovering drugs and biological substances as well as at further stages including clinical trials, commercialization of products and evaluation of their results. Biotechnology companies began to appear. However, they did not compete with large pharmaceutical companies but filled the gap in new fields of science including molecular genetics, protein chemistry and enzymology [Whittaker, Bower 1994]. It became possible due to the development of genetic engineering and the openness of biotechnology companies to innovation and creative financing strategies. At the same time, it was a period in which the pharmaceutical sector was inextricably linked to the biotechnology industry. At the beginning of the 21st century, however, there appeared other problems related to competition from generic manufacturers. For this reason, companies had to secure revenues from existing products and focus on providing them with effective patent protection. This diverted their attention from medical discoveries that should be at the core of the highly innovative companies in the biopharmaceutical sector. As a consequence, drugs that were developed differed from the previous solutions only to a small extent but still required large, long and complex clinical trials. This caused the need to effectively search for funds to cover the costs of clinical trials. In the situation when these funds were missing, the existing funds dedicated to the discovery phase had to be moved to the phases of the final clinical trials. Those practices adversely affected the innovativeness of the entire sector. It should be noted that at some point patents for the main drugs in the product portfolio began to fade, which led to the phenomenon of a patent cliff [Munos, Chin 2011]. Currently, the situation of the biopharmaceutical sector seems to be stable, although the drug development process is expensive and the uncertainty associated with raising funds for financing research and development (R&D) activities is high. In order to ensure efficiency in generating value, companies go beyond the experience created within the organization towards cooperation with other entities. In this way, the era of the monopoly on knowledge ends, and a new logic of innovation begins, reflected in the paradigm of open innovations, which changed the role of the research function. In the open innovation model, people responsible for generating knowledge become knowledge brokers at the same time, care about building relationships with people or external institutions and support processes of sharing information in a safe and reasonable way [Lin 2012; Cooper 2013; Olejniczak et al. 2014]. In practice, this direction has resulted in an increase in the number of technology transfers and the diffusion of know-how among entities involved in R&D. This was possible due to the increasing number of strategic alliances and various types of partnership agreements. The specificity of R&D activity of biopharmaceutical companies is significantly different from this type of activity carried out by entities from other high technology sectors. Biopharmaceutical companies conduct activities aimed at the welfare of society and the protection of human health. In this way, they take accountability towards society, in particular towards patients, doctors and public health insurance institutions. Disclosing information about R&D activities and related issues is of great importance for building the reputation of the organization and creating value for a wide range of stakeholders. It should be emphasized that currently organizations control a huge amount of tangible and intangible assets, which gives managers undisputed power [Maruszewska 2015]. The results of longitudinal studies show that at the end of the 1980s about 80% of the companies' values were generated through the involvement of tangible resources, and only 20% through intangible ones. Two decades later, only about 30% of the companies' values were generated by tangible resources whereas intangibles began to have an increasing share in creating value [Blair, Kochan 2000]. The development of the importance of intangible resources in organizations and their use in R&D processes contributes to the value creation in the form of new innovative products, technologies or knowledge ensuring the economic growth of the organization in long-term. One of the accounting tasks is communicating on the use of controlled resources to a wide range of stakeholders interested in the impacts of the company's activity on a community [Maruszewska 2015, p. 181]. An important issue is also reporting on activities that lead to the transformation of the expenditures involved in the organization into the expected effects and desired results for the entity and its stakeholders. Due to the fact that the R&D processes are long and at every stage determined by the strict regulations the anticipated outcomes may be uncertain or significantly shifted in time. Therefore, from the viewpoint of capital market participants, additional non-financial disclosures in this area are well perceived and expected as they can contribute to the reduction of the cost of capital and information asymmetry between the management and investors [Botosan 1997; Botosan, Plumlee 2002]. In this context, voluntary disclosures also increase the economic value of the company's assets when they relate to reporting on intangible resources, some of which may not be fully reflected in traditional financial statements [Coff et al. 2007]. In addition, the disclosure of certain non-financial information about R&D may be aimed at reducing incentives for competitors to enter the market in which a company operates [Dontoh 1989]. Empirical research included in this monograph contributed to the implementation of three research objectives. First of all, the thematic ranges of nonfinancial disclosures in the area of R&D activities of biopharmaceutical companies were recognized. Secondly, the contexts of non-financial disclosures and factors differentiating the companies in terms of adopting a given context were established. Thirdly, factors significantly influencing the level of non-financial disclosures in the area of R&D activities in biopharmaceutical companies were identified. An achievement of the research objectives was possible due to the realization of partial objectives in the particular chapters of the monograph. The first chapter depicts the biopharmaceutical sector and the conditioning of its R&D activities. The identification and classification of stakeholders in biopharmaceutical companies are an important contribution in this part of the monograph. It was indicated how individual stakeholders can be involved in the organization's activities. Forms of these relations were described due to the degree of stakeholders' impact on the company and the level of their interest in organization's activities. The second chapter explains the theoretical foundations justifying disclosures in corporate reporting, defines the legal framework and indicates projects and recommendations relating to non-financial reporting. The clarification and systematization of issues related to R&D was the significant contribution in this part of the work. The terms such as intangible resources, intellectual capital and intangible assets were explained with reference to terminology appearing in literature and legal regulations. The third chapter describes the methodology of examining non-financial narratives. It focuses on content analysis, methods of text exploration, readability studies, linguistic and sentiment analyses. Identification of the goals of non-financial narrative analysis with reference to annual reporting is an important contribution in this part of the monograph. These goals include the examination of: (1) the texts' attributes, (2) the premises and determinants of disclosures and (3) the consequences of disclosures. The fourth chapter reviews the current state of the art in the area of disclosures on R&D activities and highlights the results of the empirical research studies on these issues. The main contribution in this chapter was to distinguish six groups of factors that were supposed to have an impact on R&D disclosures. These factors included: (1) company size, (2) length of the listing period on the capital market, (3) corporate governance (i.e. ownership structure, board size, independence of non-executive directors or members of supervisory boards, independence of committees on the boards of directors/supervisory boards, CEO duality), (4) financial categories (i.e. intensity of R&D activities, market to book ratio, indebtedness and profitability), (5) accounting policy and (6) external factors (i.e. listing status, sector affiliation, auditor's type, barriers to market entry, legal system and increase in disclosure quality of other entities in the sector). The research results presented in the last chapter are an empirical evidence of the complex activities of biopharmaceutical companies in the rapidly growing innovative high technology sector. These results constitute the author's own contribution to the discipline of economics and finance; in this respect that due to the achievement of the research objectives, two gaps (cognitive and research) were closed. The cognitive gap resulted from the lack of research studies on the area of nonfinancial disclosures in broadly understood R&D activity in reference to biopharmaceutical companies. This monograph fills this gap since it is the first thematic publication on the Polish market on a topic that seems to be an important cognitive area from the viewpoint of biopharmaceutical companies and their broad range of stakeholders. The research gap consisted in the fact that empirical studies have not yet analysed the broader context of non-financial R&D disclosures taking into account the external environment, which implies many activities and events of great importance for R&D area. The proposed model index of non-financial disclosures consisting of six important categories that referred to the areas of R&D activities closed the research gap. The structure of the proposed disclosure index may be justified by the conclusions of the voluntary disclosures guidelines, the composition of the indices developed by other authors and the results of own exploratory studies of annual reports of biopharmaceutical companies. The said disclosure index served to empirically identify factors that might significantly affect the level of non-financial disclosures in the area of R&D activities. The empirical research carried out in the fifth chapter consisting in the exploration and analysis of the narrative included in the annual reports enabled to identify six main thematic modules around which the discussion regarding R&D activity oscillated. The most frequently discussed issues included the following areas: clinical studies, development projects, new products, external environment and accounting policy in the R&D field. These topics have been illustrated on the co-occurrence network representing the relations between the most common words. The results achieved at this stage of the research procedure were used to implement the next two objectives. First of all, the contexts of non-financial disclosures and factors differentiating the companies in terms of adopting a specific context were established. That objective was achieved due to the cluster analysis based on the agglomeration method. For this purpose the vectors of the most common words referring to the R&D activity of individual companies were applied. The examined companies were grouped in terms of similarities in the area of disclosed non-financial issues related to R&D. The evaluation of the content of disclosed non-financial information enabled to observe three approaches adopted by the examined entities and make a synthesis by defining the contexts of disclosures in R&D area. The first approach consisted in presenting a reliable and transparent description of R&D accounting policy (regulatory context of disclosures). The second approach was based on disclosing prospective information on R&D (strategic context of disclosures), whereas the last one consisted in disclosing current issues related with R&D (operational context of disclosures). As part of the implementation of the second objective, relations between the contexts of the discussion and some variables such as R&D costs, R&D intensity, length of annual report, length of R&D narratives and company size were also detected. In order to achieve the third objective five research hypotheses were formulated. Hypothesis 1: The dispersed ownership structure has a positive impact on the level of non-financial disclosures in the area of R&D activity. Hypothesis 2: The size of the company has a positive impact on the level of nonfinancial disclosures in the area of R&D activity. Hypothesis 3: The length of the listing period on the capital market has a negative impact on the level of non-financial disclosures in the area of R&D activity. Hypothesis 4: The indebtedness of a company has a positive impact on the level of non-financial disclosures in the area of R&D activity. Hypothesis 5: The intensity of R&D actions has a positive impact on the level of nonfinancial disclosures in the area of R&D activity. Evidence showed that there were statistically significant relationships between the ownership dispersion and the index of non-financial disclosures in the area of R&D activity as well as between the size of the company and the said disclosure index. This confirmed the validity of the first two research hypotheses. It should be noted that these two relations were positive. In-depth studies were also carried out, including an analysis of the impacts of shareholder dispersion, company size and age, indebtedness and the intensity of R&D actions on the partial indices of nonfinancial disclosures. The results of these studies partially confirmed the empirical results obtained for the aggregate disclosure index. There were proved statistically significant positive relations between shareholder dispersion and partial disclosure indices in the areas of: (1) development, commercialization and patent protection of products, (2) organization of R&D activities and (3) external environment. Interesting conclusions were also provided by the linear regression model describing the relationship between the indicated factors and disclosures about development projects and clinical trials. It showed that both the age of the company and the intensity of R&D actions stimulated the level of disclosures in the field of development projects and clinical trials. Hence, the companies that were listed on the capital market longer and incurred high R&D costs with regards to generated revenues felt obliged to disclose more non-financial information related with medical issues such as descriptions of medical research areas, current phases of clinical trials and their results. Deliberations and research carried out in this monograph provide new knowledge on non-financial disclosures in the area of R&D activities in a much broader context that takes into account the external environment. Inclusion of this category in the aggregated disclosure index modifies the previous approaches of other authors and constitutes the scientific value of this monograph. In addition, the inclusion of disclosures on risk description in the partial indices related with development projects and clinical trials, development, commercialization and patent protection of products, organization of R&D activities and the external environment is an additional scientific distinctive feature. It is worth noticing that this monograph along with scientific values has also practical advantages. Discussion and research results presented in this work can be used primarily by Polish biopharmaceutical companies in the design of nonfinancial disclosure strategies in the area of R&D activities. Investors and stock market analysts may use this book to obtain knowledge on the area of non-financial information they may expect from biopharmaceutical companies. Finally it may be useful for the society, that is, everyone who is interested in what actions involve public funds gained from the reimbursement of medicines and what complex processes contribute to the emergence of new technologies aimed at discovering breakthrough therapies.(original abstract)

Słowa kluczowe

PL

Przemysł biofarmaceutyczny; Spółki europejskie; Sprawozdanie finansowe

EN

Biopharma industry; Societas Europea; Financial statements

• Czasopismo: Monografie i Opracowania Uniwersytetu Ekonomicznego we Wrocławiu
• Rocznik: 2019
• Numer: nr 297
• Strony: 465

Twórcy

autor

Joanna Dyczkowska

• Uniwersytet Ekonomiczny we Wrocławiu

Bibliografia

• 2014 Master Dictionary, Software Repository for Accounting and Finance, https://sraf.nd.edu/ (11.08.2018).
• AA1000AP, 2018, AccountAbility Principles, https://www.accountability.org/standards/ (20.11.2018).
• Abbott W.F., Monsen R.J., 1979, On the measurement of corporate social responsibility: Self-reported disclosures as a method of measuring corporate social involvement, Academy of Management Journal, vol. 22, no. 3, s. 501-515.
• Abdelbadie R., Elshandidy T., 2013, Determinants of voluntary disclosure on R&D expenditures: Evidence from the UK R&D intensive industries, British Accounting and Finance Annual Conference.
• Abeysekera I., 2010, The influence of board size on intellectual capital disclosure by Kenyan listed firms, Journal of Intellectual Capital, vol. 11, no. 4, s. 504-518.
• Abeysekera I., 2012, A template for integrated reporting, Journal of Intellectual Capital, vol. 14, no. 2, s. 227-245.
• Aboody D., Lev B., 2000, Information asymmetry, R&D, and insider gains, Journal of Finance, vol. 55, no. 6, s. 2747-2766.
• Abrahamson E., Amir E., 1996, The information content of the president's letter to shareholders, Journal of Business Finance and Accounting, vol. 23, no. 8, s. 1157-1182.
• Abrahamson E., Park C., 1994, Concealment of negative organizational outcomes: An agency theory perspective, Academy of Management Journal, vol. 37, no. 5, s. 1302-1334.
• Abramowicz W., Piskorski J. 2003, Information extraction from free-text business documents, [w:] Becker S.A. (red.), Effective Databases for Text and Document Management, IRM Press, s. 12-23.
• AccountAbility, 2015, AAA1000 Stakeholder Engagement Standard (SES), https://www.accountability. org/wp-content/uploads/2016/10/AA1000SES_2015.pdf (28.03.2019).
• AccountAbility, UNEP, SRA, 2005, The Stakeholder Engagement Manual, Vol. 2: The Practitioner's Handbook on Stakeholder Engagement, https://www.ccednet-rcdec.ca/sites/ccednet-rcdec.ca/files/the_stakeholder_engagement_manual_-_volume_2.pdf (19.01.2019).
• Active Biotech, 2014, Annual report, http://www.activebiotech.com/annual-reports (30.06.2015).
• Actelion, 2014, Annual report, https://www.companyreporting.com/sites/default/files/annual-report-index/actelion-annual-report-2014.pdf (30.06.2015).
• Adamska A., 2011, Systemy nadzoru korporacyjnego na świecie - tendencje zmian, Ekonomia i Prawo,Tom VII, s. 67-77.
• Adamska A., Mesjasz C., Urbanek P., 2016, Teorie ładu korporacyjnego: władanie i kontrola w złożonym świecie, Wydawnictwo Uniwersytetu Łódzkiego, Łódź.
• Adelberg A.H., 1979, Narrative disclosures contained in financial reports: Means of communication or manipulation?, Accounting and Business Research, vol. 9, no. 35, s. 179-190.
• Admiraal M., Nivra R., Turksema R., 2009, Reporting on nonfinancial information, International Journal of Government Auditing, vol. 36, no. 3, s. 15-22.
• Adrem A.H., 1999, Essays on disclosure practices in Sweden - Causes and effects, PhD dissertation, Department of Business Administration, Lund University: Lund University Press, https://lup.lub.lu.se/search/search/publication/8cbab3e1-9623-4260-850b-02ce808db300(18.01.2018).
• Aerts W., 1994, On the use of accounting logic as an explanatory category in narrative accounting disclosures, Accounting, Organizations and Society, vol. 19, no. 4/5, s. 337-353.
• Aerts W., 2005, Picking up the pieces: Impression management in the retrospective attributional framing of accounting outcomes, Accounting Organizations and Society, vol. 30, s. 493-517.
• Ahmed K., Courtis J.K., 1999, Associations between corporate characteristics and disclosure levels in annual reports: A meta-analysis, British Accounting Review, vol. 31, no. 1, s. 35-61.
• Ahn H.-J., Bae K.-H., Chan K., 2001, Limit orders, depth, and volatility: Evidence from the Stock Exchange of Hong Kong, Journal of Finance, vol. 56, no. 2, s. 767-787.
• Ahuja G., Katila R., 2001, Technological acquisitions and the innovation performance of acquiring firms, Strategic Management Journal, vol. 22, no. 3, s. 197-220.
• AICPA (American Institute of Certified Public Accountants), 1994, Improving business reporting - a customer Focus, Jenkins Committee Report, 2018-09-19, [https://www.aicpa.org/interestareas/frc/accountingfinancialreporting/enhancedbusinessreporting/jenkinscommittee.html].
• Ajinkya B., Gift M., 1984, Corporate managers' earnings forecasts and symmetrical adjustment of market expectations, Journal of Accounting Research, vol. 22, no. 2, s. 425-444.
• Akerlof G.A., 1970, Market for lemons: Quality uncertainty and the market mechanism, Quarterly Journal of Economics, vol. 84, no. 3, s. 488-500.
• Alk Abello, 2014, Annual report, http://ir.alk-abello.com/downloads.cfm?CategoryID=2560&-Year= (30.06.2015).
• Alkermes, 2014, Annual report, http://www.annualreports.com/Company/alkermes-inc (30.06.2015).
• Allegrini M., Greco G., 2013, Corporate boards, audit committees and voluntary disclosure: Evidence from Italian listed companies, Journal of Management and Governance, vol. 17, no. 1, s. 187-216.
• Allen M.W., Caillouet R.H., 1994, Legitimation endeavours: Impression management strategies used by an organization in crisis, Communication Monographs, vol. 61, no. 1, s. 44-62.
• Allergan, 2014, Annual report, http://www.annualreports.com/Company/allergan-plc (30.06.2015).
• Almirall, 2014, Annual report, https://www.almirall.com/pl/investors/download-centre/annual-reports/ (30.06.2015).
• Aluchna M., 2011, Struktura własności a nadzór korporacyjny, [w:] Dobija D., Koładkiewicz I. (red.), Ład korporacyjny, Wolters Kluwer Polska, Warszawa, s. 53-86.
• Amarin, 2014, Annual report, http://investor.amarincorp.com/annuals.cfm (30.06.2015).
• Amir E., Lev B., 1996, Value-relevance of nonfinancial information: the wireless communication industry, Journal of Accounting and Economics, vol. 22, s. 3-30.
• Amit R., Zott C., 2001, Value creation in e-business, Strategic Management Journal, vol. 22, no. 6-7, s. 493-520.
• An Y., Davey H., Eggleton I., 2011, Towards a comprehensive theoretical framework for voluntary IC disclosure, Journal of Intellectual Capital, vol. 12, no. 4, s. 571-585.
• Arora A., Fosfuri A., Gambardella A., 2001, Markets for Technology: Economics of Innovation and Corporate Strategy, MIT Press, Cambridge, MA.
• Arrow K.J., 1962, Economic welfare and the allocation of resources for inventions, [w:] National Bureau of Economic Research, The Rate and Direction of Inventive Activity, Princeton University Press, Princeton.
• Arvidsson S., 2003, The extent of disclosure on intangibles in annual reports, [w:] Proceedings of the Fourth Annual SNEE Congress in Mölle, http://www.snee.org/filer/papers/169.pdf (8.12.2016).
• Ashforth B., Gibbs B., 1990, The double-edged sword of organizational legitimation, Organization Science, vol. 1, no. 2, s. 177-194.
• Ashiq A., Chen T.Y., Radhakrishnan S., 2007, Corporate disclosure by family firm, Journal of Accounting and Economics, vol. 44, s. 238-286.
• Ashton R.H., 2005, Intellectual capital and value creation: A review, Journal of Accounting Literature, vol. 24, s. 53-134.
• Aspen Pharmacare, 2016, Annual report, https://www.aspenpharma.com/wp-content/uploads/2017/02/Aspen-IR-2016-10-Nov-2016.pdf (16.08.2018).
• ASSC, 1975, The corporate report. A discussion paper published for comment by the Accounting Standards Steering Committee, Accounting Standards Steering Committee, https://www.icaew.com/library/subject-gateways/corporate-reporting/the-corporate-report.
• Assink M., 2006, Inhibitors of disruptive innovation capability: A conceptual model, European Journal of Innovation Management, vol. 9, no. 2, s. 215-233.
• Astrazeneca, 2014, Annual report, https://www.astrazeneca.com/investor-relations/annual-reports.html (30.06.2015).
• ASX, 2013, Guidance Note 8, http://www.asx.com.au/documents/rules/Chapter03.pdf (15.04.2018).
• ASX, AusBiotech, 2013, Code of best practice for reporting by life science companies, http://www.asx.com.au/ (15.09.2017).
• Attig N., Fong W.-M., Gadhoum Y., Lang L.H.P., 2006, Effects of large shareholding on information asymmetry and stock liquidity, Journal of Banking and Finance, vol. 30, no. 10, s. 2875-2892.
• Atuahene-Gima K., 1992, Inward technology licensing as an alternative to internal R&D in new product development: A conceptual framework, Journal of Product Innovation Management, vol. 9, no. 2, s. 156-167.
• Azher A.I., 2004, Antitrust regulators and the biopharmaceutical industry: Compulsory licensing schemes ignoring gene therapy patients' needs, University of Pennsylvania Journal of International Economic Law, vol. 25, no. 1, s. 383-421.
• Babbie E., 2003, Badania społeczne w praktyce, Wydawnictwo Naukowe PWN, Warszawa.
• Baginski S., Hassell J., Kimbrough M., 2004, Why do managers explain their earnings forecasts?, Journal of Accounting Research, vol. 42, no. 1, s. 1-29.
• Ballester M., Garcia-Ayuso M., Livnat J., 2003, The economic value of the R&D intangible asset, The European Accounting Review, vol. 12, no. 4, s. 605-663.
• Barako D.G., 2007, Determinants of voluntary disclosures in Kenyan companies annual reports, African Journal of Business Management, vol. 1, no. 5, s. 113-128.
• Barako D.G., Hancock P., Izan H.Y., 2006, Relationship between corporate governance attributes and voluntary disclosures in annual reports: The Kenyan experience, Financial Reporting, Regulation and Governance (FRRaG), 5(1), n/p.
• Barro R.J., Sala-i-Martin X., 1995, Economic Growth, MIT Press, Cambridge, MA.
• Barua A., Lin S., Sbaraglia A.M., 2010, Earnings management using discontinued operations, The Accounting Review, vol. 85, no. 5, s. 1485-1509.
• Basilea Pharmaceutica, 2014, Annual report, http://www.basilea.com/Investor-Relations/Financial-reports/Archive/ (30.06.2015).
• Bavarian Nordic, 2014, Annual report, http://www.bavarian-nordic.com/investor/events.aspx?event=4207 (30.06.2015).
• Bayer, 2014, Annual report, http://www.annualreport2014.bayer.com/ (30.06.2015).
• Bąk M., 2010, Różnorodność pojęć i klasyfikacji czynników niematerialnych ze szczególnym uwzględnieniem punktu widzenia rachunkowości, Prace Naukowe Uniwersytetu Ekonomicznego we Wrocławiu, nr 127, Nauki o Finansach nr 4.
• Bąk M., 2011, Wartości niematerialne w polityce rachunkowości przedsiębiorstwa, Prace Naukowe Uniwersytetu Ekonomicznego we Wrocławiu, nr 190, s. 11-21.
• Beattie V., 2005, Moving the financial accounting research front forward: The UK contribution, British Accounting Review, vol. 37, no. 1, s. 85-114.
• Beattie V., 2014, Accounting narratives and the narrative turn in accounting research: Issues, theory, methodology, methods and a research framework, The British Accounting Review, vol. 46, no. 2, s. 111-134.
• Beattie V., Dhanani A., Jones M., 2008, Investigating presentational change in UK annual reports: A longitudinal perspective, Journal of Business Communication, vol. 45, no. 2, s. 181-222.
• Beattie V., McInnes W., Fearnley S., 2004, A methodology for analysing and evaluating narratives in annual reports: A comprehensive descriptive profile and metrics for disclosure quality attributes, Accounting Forum, vol. 28, no. 3, s. 205-236.
• Beattie V., Pratt K., 2002, Voluntary Annual Report Disclosures: What Users Want?, The Institute of Chartered Accountants of Scotland, ICAS, Edinburgh.
• Beattie V., Smith S.J., 2012, Evaluating disclosure theory using the views of UK finance directors in the intellectual capital context, Accounting and Business Research, vol. 42, no. 5, s. 471-494.
• Beattie V., Thomson S.J., 2006, Lifting the lid on the use of content analysis to investigate intellectual capital disclosures, School of Management and Languages Discussion Paper Series & Finance.
• Beever C., Pettersson A., Rotz G., Vlak A., 2010, The missing link in pharmaceutical R&D scientific leaders are essential to success, Booz & Company Inc., https://www.strategyand.pwc.com/media/file/The_Missing_Link.pdf (16.07.2018).
• Ben-Zion U., 1978, The investment aspect of non-production expenditures: An empirical test, Journal of Economics and Business, vol. 30, no. 3, s. 224-229.
• Ben-Zion U., 1984, The R&D investment decision and its relationship to the firm's market value: Some preliminary results, [w:] Griliches Z. (red.), R&D, Patents and Productivity, University of Chicago Press, Chicago.
• Berelson B., 1952, Content Analysis in Communication Research, The Free Press, Glencoe, IL.
• Berrone P., Gelabert L., Fosfuri A., 2009, The impact of symbolic and substantive actions on environmental legitimacy, IESE Business School, https://www.iese.edu/research/pdfs/di-0778-e.pdf (8.08.2018).
• Beyer A., Cohen D.A., Lys T.Z., Walther B.R., 2010, The financial reporting environment: Review of the recent literature, Journal of Accounting and Economics, vol. 50, no. 2/3, s. 296-343.
• Beyer K., 2014, Pomiar kapitału intelektualnego wskaźnikiem MV/BV, Studia i Prace Wydziału Nauk Ekonomicznych i Zarządzania, t. 1, nr 38, s. 9-19.
• Beynon M.J., Clatworthy M.A., Jones M.J., 2004, The prediction of profitability using accounting narratives: A variable-precision rough set approach, Intelligent Systems in Accounting and Finance Management, vol. 12, no. 4, s. 227-242.
• Bianchi M., Cavaliere A., Chiaroni D., Frattini F., Chiesa V., 2011, Organisational modes for open innovation in the biopharmaceutical industry: An exploratory analysis, Technovation, vol. 31, no. 1, s. 22-33.
• BioInvent International, 2014, Annual report, http://www.bioinvent.se/investors/financial-reports/annual-reports-and-interim-reports/ (30.06.2015).
• Biotest, 2014, Annual report, https://www.biotest.com/de/en/investor_relations/news_and_publications/publications/annual_reports.cfm (30.06.2015).
• Bjurklo M., 2008, Narrative accounting: A new form of management accounting?, International Studies of Management and Organization, vol. 38, no. 2, s. 25-43.
• Blacksun, 2014, The first 20 - the concise strategic report paradox. Analysis of how the FTSE 350 September year ends have responded to the changing reporting environment, http://www.blacksunplc.com (19.02.2016).
• Blair M.M., Kochan T.A. (red.), 2000, The New Relationship: Human Capital in the American Corporation, Brookings Institution Press, Washington, DC.
• Blair M.M., Wallman S.M.H., 2000, Unseen Wealth: Report of the Brookings Task Force on Intangibles, Brookings Institution Press, Washington, DC.
• Bloomfield R.J., 2002, The "incomplete revelation hypothesis" and financial reporting, Accounting Horizons, vol. 16, no. 3, s. 233-243.
• Bochenek T., 2013, Leki sieroce stosowane w chorobach rzadkich - wyzwanie dla współczesnych systemów opieki zdrowotnej, Nowiny Lekarskie, vol. 82, no. 4, s. 338-342.
• Boehringer Ingelheim, 2014, Annual report, http://annualreport.boehringer-ingelheim.com/en/download-center/pdf-downloads/ (30.06.2015).
• Bohdanowicz L., 2012, Funkcja kontrolna rady nadzorczej a redukcja kosztów agencji, Zarządzanie i Finanse, nr 4, cz. 1, s. 53-68.
• Bohdanowicz L., 2014, Udział pracowników w radach nadzorczych polskich spółek publicznych, [w:] Stabryła A., Wawak S. (red.), Problemy zarządzania organizacjami w społeczeństwie informacyjnym, Mfiles.pl, seria Encyklopedia Zarządzania, Kraków, s. 117-128.
• Bohdanowicz L., 2016, Własność menedżerska w polskich spółkach publicznych, Wydawnictwo Uniwersytetu Łódzkiego, Łódź.
• Bolan R.S., 1999, Rationality revisited: An alternative perspective on reason in management and planning, Journal of Management History, vol. 5, no. 2, s. 68-86.
• Boland R.J., Pondy L.R., 1983, Accounting in organizations: A union of natural and rational perspectives, Accounting Organizations and Society, vol. 8, no. 2/3, s. 223-234.
• Bontis N., 1998, Intellectual capital: An exploratory study that develops measures and models, Management Decision, vol. 36, no. 2, s. 63-76.
• Bontis N., Dragonetti N.C., Jakobsen K., Ross G., 1999, The knowledge toolbox: A review of the tools available to measure and manage intangible resources, European Management Journal, vol. 17, no. 4, s. 391-402.
• Boo E., Simnett R., 2002, The information content of management's prospective comments in financially distressed companies: A note, Abacus, vol. 38, no. 2, s. 280-295.
• Boone A.L., Floros I.V., Johnson S.A., 2016, Redacting proprietary information at the Initial Public Offering, Journal of Financial Economics, vol. 120, no. 1, s. 102-123.
• Boone J., Raman K., 1998, Unrecognized R&D assets and the market microstructure, Working Paper, Mississippi State University.
• Borowiecki R., Kusio T., 2016, Zwiększanie zasobów kompetencyjnych przedsiębiorstw poprzez współpracę z uczelniami, Zarządzanie i Finanse. Journal of Management and Finance, vol. 14,no. 2, s. 71-90.
• Botosan C.A., 1997, Disclosure level and the cost of equity capital, The Accounting Review, vol. 72, no. 3, s. 323-349.
• Botosan C.A., Plumlee M.A., 2002, A re-examination of disclosure level and the expected cost of equity capital, Journal of Accounting Research, vol. 40, no. 1, s. 21-40.
• Boudreau K.J., Lakhani K.R., 2015, "Open" disclosure of innovations, incentives and follow-on reuse: Theory on processes of cumulative innovation and a field experiment in computational biology, Research Policy, vol. 44, no. 1, s. 4-19.
• Boujelbene M.B., Affes H., 2013, The impact of intellectual capital disclosure on cost of equity capital: A case of French firms, Journal of Economics, Finance and Administrative Science, vol. 18, no. 34, s. 45-53.
• Bowen R.M., Davis A.K., Matsumoto D.A., 2005, Emphasis on pro forma versus GAAP earnings in quarterly press releases: Determinants, SEC intervention, and market reactions, The Accounting Review, vol. 80, no. 4, s. 1011-1038.
• Bozzolan S., Favotto F., Ricceri F., 2003, Italian annual intellectual capital disclosure. An empirical analysis, Journal of Intellectual Capital, vol. 4, no. 4, s. 543-558.
• Bradley J., 1993, Methodological issues and practices in qualitative research, Library Quarterly, vol. 63, no. 4, s. 431-449.
• Bralczyk J. (red.), 2005, Słownik 100 tysięcy potrzebnych słów, Wydawnictwo Naukowe PWN, Warszawa.
• Branco M., Rodrigues L., 2008, Factors influencing social responsibility disclosure by Portuguese companies, Journal of Business Ethics, vol. 83, no. 4, s. 685-701.
• Brennan N., 2001, Reporting intellectual capital in annual reports: Evidence from Ireland, Accounting, Auditing and Accountability Journal, vol. 14, no. 4, s. 423-436.
• Bricker R., Previts G., Robinson T., Young S., 1995, Financial analyst assessment of company earnings quality, Journal of Accounting, Auditing and Finance, vol. 10, no. 3, s. 541-555.
• Brockman P., Chung D.Y., 2001, Managerial timing and corporate liquidity: Evidence from actual share repurchases, Journal of Financial Economics, vol. 61, no. 3, s. 417-448.
• Brooking A., 1998, Intellectual Capital: Core Asset for the Third Millennium Enterprise, International Thomson Business Press, London.
• Brown J.S., 2003, Innovating innovation, www.johnseelybrown.com/fwd_openinnovation.html (6.08.2017).
• Brown N., Deegan C., 1998, The public disclosure of environmental performance information - A dual test of media agenda setting theory and legitimacy theory, Accounting and Business Research, vol. 29, no. 1, s. 21-41.
• Brown P., Beekes W., Verhoeven P., 2011, Corporate governance, accounting and finance: A review, Accounting and Finance, vol. 51, no. 1, s. 96-172.
• Bryan S.H., 1997, Incremental information content of required disclosures contained in management discussion and analysis, The Accounting Review, vol. 72, no. 2, s. 285-301.
• BTG, 2014, Annual report, http://www.annualreports.com/Company/btg-plc (30.06.2015).
• Bukh P.N., Larsen H.T., Mouritsen J., 2001, Constructing intellectual capital statements, Scandinavian Journal of Management, vol. 17, no. 1, s. 87-108.
• Bukh P.N., Nielsen C., Gormsen P., Mouritsen J., 2005, Disclosure of information on intellectual capital in Danish IPO prospectuses, Accounting, Auditing and Accountability Journal, vol. 18, no. 6, s. 713-732.
• Bushee B., Leuz C., 2005, Economic consequences of SEC disclosure regulation: Evidence from the OTC Bulletin Board, Journal of Accounting and Economics, vol. 39, no. 2, s. 233-264.
• Bushman R.M., Piotroski J.D., Smith J.A., 2004, What determines corporate transparency?, Journal of Accounting Research, vol. 42, no. 2, s. 207-252.
• Byczko S., Trzmielak D.M., 2011, Zagadnienia własności intelektualnej w transferze technologii, Polska Agencja Rozwoju Przedsiębiorczości, Warszawa.
• Byczko S., Trzmielak D.M., 2013, Własność intelektualna na uczelni i w działalności gospodarczej. Analiza porównawcza i praktyczne aspekty funkcjonowania systemu patentowania w Polsce i wybranych krajach, Centrum Transferu Technologii, Uniwersytet Łódzki.
• Cadbury Committee Report, 1992, Report of the Cadbury Committee on the financial aspects of corporate governance, Gee, London, https://www.icaew.com/library/subject-gateways/corporate-governance/codes-and-reports/cadbury-report (3.08.2018).
• Camfferman K., 1997, Voluntary annual report disclosure by listed Dutch companies, 1945-1983, Garland, Hamden, CT.
• Campbell D., Shrives P., Bohmbach-Saager H., 2001, Voluntary disclosure of mission statements in corporate annual reports: Signalling what and to whom?, Business and Society Review, vol. 106, no. 1, s. 65-87.
• Campbell D., Slack R., 2008, Narrative reporting: Analysts' perceptions of its value and relevance, The Association of Chartered Certified Accountants, London.
• Cazavan-Jeny A., Jeanjean T., 2006, The negative impact of R&D capitalization: A value relevance approach, European Accounting Review, vol. 15, no. 1, s. 37-61.
• Cellectis, 2014, Annual report, https://www.cellectis.com/uploads/files/annual_report_2014.pdf (30.06.2015).
• Cerbioni F., Parbonetti A., 2007, Exploring the effects of corporate governance on intellectual capital disclosure: An analysis of European biotechnology companies, European Accounting Review, vol. 16, no. 4, s. 791-826.
• Chan L.K.C., Lakonishok J., Sougiannis T., 2001, The stock market valuation of research and development expenditures, The Journal of Finance, vol. 56, no. 6, s. 2431-2456.
• Chan S.H., Martin J.D., Kensinger J.W., 1990, Corporate research and development expenditures and share value, Journal of Financial Economics, vol. 26, no. 2, s. 255-276.
• Chau G.K., Gray S.J., 2002, Ownership structure and corporate voluntary disclosure in Hong Kong and Singapore, The International Journal of Accounting, vol. 37, no. 2, s. 247-265.
• Chaudhuri S., Tabrizi B., 1999, Capturing the real value in high-tech acquisitions, Harvard Business Review, vol. 77, no. 5, s. 123-130.
• Chen S., Miao B., Shevlin T.J., 2015, A new measure of disclosure quality: The level of disaggregation of accounting data in annual reports, https://ssrn.com/abstract=2475624; http://dx.doi.org/10.2139/ssrn.2475624.
• Cheng E.C.M., Courtenay S.M., 2006, Board composition, regulatory regime and voluntary disclosure, International Journal of Accounting, vol. 41, no. 3, s. 262-289.
• Chesbrough H.W., 2003, Open Innovation: The New Imperative for Creating and Profiting from Technology, wyd. 1, Harvard Business School Press, Boston.
• Chesbrough H.W., 2006a, Open Innovation: The New Imperative for Creating and Profiting from Technology, wyd. 2, Harvard Business School Press, Boston.
• Chesbrough H.W., 2006b, Open Business Models: How to Thrive in the New Innovation Landscape, Harvard Business School Press, Boston.
• Chesbrough H.W., Crowther A.K., 2006, Beyond high-tech: Early adopters of open innovation in other industries, R&D Management, vol. 36, no. 3, s. 229-236.
• Chesbrough H.W., Rosenbloom R., 2002, The role of business model in capturing value from innovations: Evidence from Xerox corporation's technology spin-off companies, Industrial Corporate Change, vol. 11, no. 3, s. 529-555.
• Chiaroni D., Chiesa V., Frattini F., 2009, Investigating the adoption of open innovation in the biopharmaceutical industry: A framework and an empirical analysis, European Journal of Innovation Management, vol. 12, no. 3, s. 285-305.
• Cho C.H., Roberts R.W., Patten D.M., 2010, The language of US corporation environmental disclosure, Accounting, Organizations and Society, vol. 35, no. 4, s. 431-443.
• Chordia T., Roll R., Subrahmanyam A., 2001, Market liquidity and trading activity, Journal of Finance, vol. 56, no. 2, s. 501-530.
• Chow C.W., Wong-Boren A., 1987, Voluntary financial disclosure by Mexican corporations', Accounting Review, vol. 62, no. 3, s. 533-541.
• Chr. Hansen, 2014, Annual report, http://www.chr-hansen.com/en/investors/reports-and-presentations (30.06.2015).
• Christensen C.M., Waldeck A., Fogg R., 2017, How disruptive innovation can finally revolutionize healthcare. A plan for incumbents and start-ups to build a future of better health and lower costs, Industry Horizona, Innosight Executive Briefing, https://www.christenseninstitute.org/wp-content/uploads/2017/05/How-Disruption-Can-Finally-Revolutionize-Healthcare-final.pdf (31. 08.2017).
• Christensen J.F., 1996, Innovative assets and inter-asset linkages - a resource-based approach to innovation, Journal Economics of Innovation and New Technology, vol. 4, no. 3, s. 193-210.
• Christensen J.F., 2010, Building innovative assets and dynamic coherence in multi-technology companies, [w:] Foss N.J., Robertson P.L. (red.), Resources, Technology and Strategy: Explorations in the Resource-based Perspective, Routledge, London, s. 121-148.
• Chua W.F., 1986, Radical developments in accounting thought, The Accounting Review, vol. 61, no. 4, s. 601-632.
• Church K.W., Hanks P., 1990, Word association norms, mutual information, and lexicography, Computational Linguistics, vol. 16, s. 22-29.
• Cieślak I., 2011, Komitet do spraw wynagrodzeń, [w:] Dobija D., Koładkiewicz I., Cieślak I., Klimczak K. (red.), Komitety rad nadzorczych, Wolters Kluwer Polska, Warszawa, s. 100-124.
• Circassia, 2014, Annual report, http://www.circassia.com/investors/financial-reports/ (30.06.2015).
• Clark J.W., 2015, Financial narratives of U.S. biotechnology companies before, during, and after the great recession, Education Doctoral, Paper 217.
• Clarkson P., Kao J., Richardson G., 1999, Evidence that management discussion and analysis (MD&A) is a part of a firm's overall disclosure package, Contemporary Accounting Research, vol. 16, no. 1, s. 111-134.
• Clarkson P.M., Kao J.L., Richardson G.D., 1994, The voluntary inclusion of forecasts in the MD&A section of annual reports, Contemporary Accounting Research, vol. 11, no. 1, s. 423-450.
• Clatworthy M., Jones M.J., 2001, The effect of thematic structure on the variability of annual report readability, Accounting, Auditing and Accountability Journal, vol. 14, no. 3, s. 311-326.
• Clatworthy M., Jones M.J., 2006, Differential patterns of textual characteristics and company performance in the chairman's statement, Accounting, Auditing and Accountability Journal, vol. 19, no. 4, s. 493-511.
• Clinch G., Verrecchia R.E., 1997, Competitive disadvantage and discretionary disclosure in industries, Australian Journal of Management, vol. 22, no. 2, s. 125-137.
• Coebergh H., 2011, Voluntary disclosure of corporate strategy: Determinants and outcomes. An empirical study into the risks and payoffs of communicating corporate strategy, Doctoral thesis, School of Management, University of Bradford.
• Coff R.W., Lee P.M., Hayward S., 2007, Corporate disclosure of competitive advantages: Why firms direct attention toward their breakthroughs, Working Paper, Goizueta Business School, Emory University, Atlanta, GA.
• Coleman M., Liau T.L., 1975, A computer readability formula designed for machine scoring, Journal of Applied Psychology, vol. 60, no. 2, s. 283-284.
• Coller M., Yohn T., 1997, Management forecasts and information asymmetry: An examination of bid-ask spreads, Journal of Accounting Research, vol. 35, no. 2, s. 181-191.
• Collins D., Maydew E., Weiss I., 1997, Changes in the value relevance of earnings and book values over the last forty years, Journal of Accounting and Economics, vol. 24, no. 1, s. 39-67.
• Connelly B.L., Certo S.T., Ireland R.D., Reutzel C.R., 2011, Signalling theory: A review and assessment, Journal of Management, vol. 37, no. 1, s. 39-67.
• Contractor F.J., Lorange P. (red.), 2002, Cooperative Strategies and Alliances, Elsevier Science, Amsterdam.
• Cooke T.E., 1989a, Disclosure in the corporate annual reports of Swedish companies, Accounting and Business Research, vol. 19, no. 74, s. 113-124.
• Cooke T.E., 1989b, Voluntary corporate disclosure by Swedish companies, Journal of International Financial Management and Accounting, vol. 1, no. 2, s. 171-195.
• Cooper A., 2013, Research mediation in education: A typology of research brokering organizations that exist across Canada, Alberta Journal of Educational Research, vol. 59, no. 2, s. 181-207.
• Cordazzo M., Vergauwen P.G.M.C., 2012, Intellectual capital disclosure in the UK biotechnology IPO prospectuses, Journal of Human Resource Costing and Accounting, vol. 16, no. 1, s. 4-19.
• Coriat B., Orsi E., 2002, Establishing a new intellectual property regime in the United States: Origins, content and problems, Research Policy, vol. 31, no. 8, s. 1491-1507.
• Cormier D., Magna M., van Velthoven B., 2005, Environmental disclosure quality in large German companies: Economic incentives, public pressures or institutional conditions? European Accounting Review, vol. 14, no. 1, s. 3-39.
• Cosmo Pharmaceuticals, 2014, Annual report, http://www.cosmopharma.com/investor-relations/financial-reports (30.06.2015).
• Courtis J., 1995, Readability of annual reports: Western versus Asian evidence, Accounting, Auditing and Accountability Journal, vol. 8, no. 2, s. 4-17.
• Coyne K.P., 1986, Sustainable competitive advantage: What it is and what it isn't, Business Horizons, vol. 29, no. 1, s. 54-61.
• CR, 2018, Corporate Register Reporting Awards, Corporate Register, http://www.corporateregister.com/crra/ (14.08.2018).
• Crane P.A., 2006, Texture in text: A discourse analysis of a news article using Halliday and Hasan's model of cohesion, Journal of School of Foreign Languages, vol. 30, s. 131-156.
• Cravens K.S., Wallace W.A., 2001, A framework for determining the influence of the corporate board of directors in accounting studies, Corporate Governance: An International Review, vol. 19, no. 1, s. 2-24.
• Crawford V.P., Sobel J., 1982, Strategic information transmission, Econometrica, vol. 50, no. 6, s. 1431-1451.
• Crossley S.A., Allen D.B., McNamara D.S., 2011, Text readability and intuitive simplification: A comparison of readability formulas, Reading in a Foreign Language, vol. 23, no. 1, s. 84-101.
• Cuganesan S., 2005, Intellectual capital-in-action and value creation: A case study of knowledge transformations in an innovation project, Journal of Intellectual Capital, vol. 6, no. 3, s. 357-373.
• Cumming B.S., 1998, Innovation overview and future challenges, European Journal of Innovation Management, vol. 1, no. 1, s. 21-30.
• Cytos Biotechnology, 2014, Annual report, http://www.cytos.com/uploads/Reports_and_Presentations/Cytos_FY_2014_EN.pdf (30.06.2015).
• Czop K., 2013, Wiedza i kapitał intelektualny przedsiębiorstwa a zdolność organizacji do wprowadzania innowacji, [w:] Jegorow D., Niedużak A., (red.), Wpływ sektora B + R na wzrost konkurencyjności polskiej gospodarki poprzez rozwój innowacji, t. 2, Civis, Chełm, s. 88-104.
• Da Silva S.M.T., de Carvalho Morais A.I.A.P., Curto J.D., 2013, Disclosure of R&D activities, International Network of Business and Management, vol. 1, no. 4, s. 391-417.
• Daga R., Koufopoulos D.N., 2010, Disclosure and corporate governance in developing countries: Evidence from India, working paper, the British Academy of Management Conference, Management Research in a Changing Climate, The University of Sheffield, Sheffield, UK, September 14-16, 2010.
• Dale E., Chall J.S., 1948, A formula for predicting readability, Educational Research Bulletin, vol. 27, s. 37-54.
• Damanpour F., 1996, Organizational complexity and innovation: Developing and testing multiple contingency models, Management Science, vol. 42, no. 5, s. 693-716.
• Davenport T.H., Prusak L., 1998, Working knowledge: How organizations manage what they know, Harvard Business School Press, Boston.
• Davis A., Piger J., Sedor L., 2008, Beyond the numbers: Managers' use of optimistic and pessimistic tone in earnings press releases, Working Paper, University of Oregon, Eugene, OR.
• De Beaugrande R., Dressler W., 1981, Introduction to Text Linguistics, Longman, London, New York.
• De Loo I., Cooper S., Manochin M., 2015, Enhancing the transparency of accounting research: The case of narrative analysis, Qualitative Research in Accounting and Management, vol. 12, no. 1, s. 34-54.
• De Sola Pool I. (red.), 1959, Trends in Content Analysis, University of Illinois Press, Urbana, IL.
• De Villiers C., Hsiao P.-C.K., Maroun W., 2017, Developing a conceptual model of influences around integrated reporting, new insights and directions for future research, Meditari Accountancy Research, vol. 25, no. 4, s. 450-460.
• Dedman E., Lin S.W.J., Prakash A.J., Chang C.H., 2008, Voluntary disclosure and its impact on share prices: Evidence from the UK biotechnology sector, Journal of Accounting and Public Policy, vol. 27, no. 3, s. 195-216.
• Deegan C., 2000, Financial Accounting Theory, McGraw-Hill, Sydney.
• Deegan C., 2002, Introduction: The legitimising effect of social and environmental disclosures - a theoretical foundation, Accounting, Auditing and Accountability Journal, vol. 15, no. 3, s. 282-311.
• Deegan C., Blomquist C., 2006, Stakeholder influence on corporate reporting: An exploration of the interaction between WWF Australia and the Australian Minerals Industry, Accounting, Organizations and Society, vol. 31, no. 4/5, s. 343-372.
• Deegan C., Gordon B., 1996, A study of the environmental disclosure practices of Australian corporations, Accounting and Business Research, vol. 26, no. 3, s. 187-199.
• Deegan C., Unerman J., 2011, Financial Accounting Theory, McGraw-Hill Education, New York.
• Deloitte, 2017, Life sciences accounting and financial reporting update - interpretive guidance on revenue recognition under ASC 606, https://www2.deloitte.com/content/dam/Deloitte/us/Documents/audit/us-audit-interpretive-guidance-on-revenue-recognition-under-asc-606.pdf (3.08.2017).
• Deloitte, 2018, Global life sciences outlook. Innovating life sciences in the fourth industrial revolution: Embrace, build, grow, https://www2.deloitte.com/content/dam/Deloitte/global/Documents/Life-Sciences-Health-Care/gx-lshc-ls-outlook-2018.pdf (6.09.2018).
• Demil B., Lecocq X., 2010, Business model evolution: In search of dynamic consistency, Long Range Planning, vol. 43, no. 2/3, s. 227-246.
• Denicolò V., Franzoni L.A., 2004, The contract theory of patents, International Review of Law and Economics, vol. 23, no. 4, s. 365-380.
• Denning S., 2006, Effective storytelling: Strategic business narrative techniques, Strategy and Leadership, vol. 34, no. 1, s. 42-48.
• Denzin N.K., Lincoln Y., 2005, Introduction: The discipline and practice of qualitative research, [w:] Denzin N.K., Lincoln Y.L. (red.), Handbook of Qualitative Research, Sage Publications, Thousand Oaks, CA, s. 1-32.
• Depoers F., 2000, A cost-benefit study of voluntary disclosure: Some empirical evidence from French listed companies, European Accounting Review, vol. 9, no. 2, s. 245-263.
• Deumes R., 2008, Corporate risk reporting: A content analysis of narrative risk disclosures in prospectuses, Journal of Business Communication, vol. 45, no. 2, s. 120-157.
• Dewar R.D., Dutton J.E., 1986, The adoption of radical and incremental innovations: An empirical analysis, Management Science, vol. 32, s. 1422-1433.
• Diamond D.W., Verrecchia R.E., 1991, Disclosure, liquidity, and the cost of capital, The Journal of Finance, vol. 46, no. 4, s. 1325-1359.
• Diasorin, 2014, Annual report, http://www.diasorin.com/en/documenti/annual-report-2014 (30.06.2015).
• DiMaggio P., Powell W., 1983, The iron cage revisited: Institutional isomorphism and collective rationality in organizational fields, American Sociological Review, vol. 48, no. 2, s. 147-160.
• Ding Y., Entwistle G., Stolowy H., 2004, International differences in R&D disclosure practices: Evidence in a French and Canadian context, Advances in International Accounting, vol. 17, s. 55-72.
• Dobija D., 2003, Pomiar i sprawozdawczość kapitału intelektualnego przedsiębiorstwa, Wydawnictwo Wyższej Szkoły Przedsiębiorczości i Zarządzania im. Leona Koźmińskiego, Warszawa.
• Dobija D., 2011, Komitet audytu, [w:] Dobija D., Koładkiewicz I., Cieślak I., Klimczak K. (red.), Komitety rad nadzorczych, Wolters Kluwer Polska, Warszawa, s. 39-63.
• Donaldson T., Preston L., 1995, The stakeholder theory of the corporation: Concepts, evidence, and implications, Academy of Management Review, vol. 20, no. 1, s. 65-91.
• Donnelly R., Mulcahy M., 2008, Board structure, ownership, and voluntary disclosure in Ireland, Corporate Governance, vol. 16, no. 5, s. 416-427.
• Dontoh A., 1989, Voluntary disclosure, Journal of Accounting, Auditing and Finance vol. 4, no. 4, s. 480-511.
• Dosi G., Freeman C., Nelson R., Silverberg G., Soete L. (red.), 1988, Technological Change and Economic Theory, Pinter, London.
• Dowling G.R., 2006, Communicating corporate reputation through stories, California Management Review, vol. 49, no. 1, s. 82-100.
• Dowling J., Pfeffer J., 1975, Organisational legitimacy: Social values and organisational behaviour, Pacific Sociological Review, vol. 18, no. 1, s. 122-136.
• Dreyer L.G., 1984, Readability and responsibility, Journal of Reading, vol. 27, no. 4, s. 334-338.
• Drieger P., 2013, Semantic network analysis as a method for visual text analytics, Procedia - Social and Behavioral Sciences, vol. 79, s. 4-17.
• Drucker P.F., 1998, On the Profession of Management, Harvard Business School Press, Boston.
• Drucker P.F., 2004, Innowacja i przedsiębiorczość, Emka, Warszawa.
• Du Toit E., 2017, The readability of integrated reports, Meditari Accountancy Research, vol. 25, no. 4, s. 629-653.
• Duchesneau T.D., Cohn S., Dutton J., 1979, A Study of Innovation in Manufacturing: Determination, Processes and Methodological Issues, vol. I, Social Science Research Institute, University of Maine, Orono.
• Dudek H., 2005, Wykrywanie współliniowości za pomocą scentrowanych, niescentrowanych oraz uogólnionych czynników inflacji wariancji, [w:] Jajuga K., Walesiak M. (red.), Klasyfikacja i analiza danych - teoria i zastosowania, Taksonomia 12, Wydawnictwo Akademii Ekonomicznej we Wrocławiu, Wrocław, s. 613-622.
• Dumay J.C., 2008, Narrative disclosure of intellectual capital. A "structurational" analysis, Management Research News, vol. 31, no. 7, s. 518-537.
• Dunlup-Hinkler D., Kotabe M., Mundambi R., 2010, A story of breakthrough versus incremental innovation: Corporate entrepreneurship in the global pharmaceutical industry, Strategic Entrepreneurship Journal, vol. 4, s. 106-127.
• Durham E., Baker H., Smith M., Moore E., Morgan V., 2014, The BiodivERsA Stakeholder Engagement Handbook, BiodivERsA, Paris.
• Duysters G., Hagedoorn J., 2000, A note on organizational modes of strategic technology partnering, Journal of Scientific and Industrial Research, vol. 59, no. 8, s. 640-649.
• Dyckman T.R., 1964, On the investment decision, Accounting Review, vol. 39, no. 2, s. 285-295.
• Dyczkowska J., 2015a, Ujawnianie informacji strategicznych w raportach rocznych spółek notowanych na rynkach alternatywnych w Londynie i w Warszawie, Prace Naukowe Uniwersytetu Ekonomicznego we Wrocławiu, nr 389, s. 70-83.
• Dyczkowska J., 2015b, To what extent companies listed on alternative investment markets disclose strategic information in their annual reports? Comparative case studies, Prace Naukowe Uniwersytetu Ekonomicznego we Wrocławiu, nr 399, s. 153-167.
• Dyczkowska J., 2015c, Raportowanie zintegrowane - obecne i przyszłe kierunki badań oraz oczekiwane korzyści, [w:] Micherda B. (red.), Sprawozdawczość i rewizja finansowa. Uwarunkowania ekonomiczne, społeczne i regulacyjne, Wydawnictwo Uniwersytetu Ekonomicznego w Krakowie, Kraków, s. 94-104.
• Dyczkowska J., 2015d, Nowe wyzwania dla spółek w zakresie sprawozdawczości: ujawnienia finansowe i pozafinansowe według Międzynarodowych Ram Raportowania Zintegrowanego, Prace Naukowe Uniwersytetu Ekonomicznego we Wrocławiu, nr 374, s. 30-41.
• Dyczkowska J., 2016a, Do annual reports communicate strategic issues? Insight into reporting practices of high-tech companies, Prace Naukowe Uniwersytetu Ekonomicznego we Wrocławiu, nr 441, s. 47-64.
• Dyczkowska J., 2016b, Prezentacja kosztów B + R w raportach rocznych europejskich spółek biotechnologicznych, Prace Naukowe Uniwersytetu Ekonomicznego we Wrocławiu, nr 424, s. 60-71.
• Dyczkowska J., 2016c, Ujawnienia pozafinansowe dotyczące działań badawczo-rozwojowych w sprawozdaniach zarządu spółek biotechnologicznych, Studia Ekonomiczne. Zeszyty Naukowe Uniwersytetu Ekonomicznego w Katowicach, nr 284, s. 128-139.
• Dyczkowski T., 2016, Analiza dokonań OPP, prezentowanych w ich sprawozdaniach rocznych z wykorzystaniem metody drążenia tekstu, Studia Ekonomiczne. Zeszyty Naukowe Uniwersytetu Ekonomicznego w Katowicach, nr 274, s. 57-66.
• Dye R.A., 1985, Disclosure of non-proprietary information, Journal of Accounting Research, vol. 23, no. 1, s. 123-145.
• Dye R.A., 2001, An evaluation of ''essays on disclosure" and the disclosure literature in accounting, Journal of Accounting and Economics, vol. 32, no. 1-3, s. 181-235.
• Dyer J., Gregersen H., Christensen C.M., 2011, The Innovator's DNA: Mastering the Five Skills of Disruptive Innovators, Harvard Business Review Press, Boston.
• EC, 2006, Reporting Intellectual Capital to Augment Research, Development and Innovation in SMEs. Report to the Commission of the High Level Expert Group on RICARDIS, European Commission,Directorate General for Research, http://ec.europa.eu/invest-in-research/pdf/download_en/2006-2977_web1.pdf (12.09.2017).
• EC, IRI, 2013, R&D ranking of the world top 2500 companies, Data World, European Commission, Industrial Research and Innovation, http://iri.jrc.ec.europa.eu/scoreboard13.html (20.07.2018).
• EC, IRI, 2014, R&D ranking of the world top 2500 companies, Data World, European Commission, Industrial Research and Innovation, http://iri.jrc.ec.europa.eu/scoreboard14.html (20.07.2018).
• EC, IRI, 2015, R&D ranking of the world top 2500 companies, Data World, European Commission, Industrial Research and Innovation, http://iri.jrc.ec.europa.eu/scoreboard15.html (20.07.2018).
• EC, IRI, 2016, R&D ranking of the world top 2500 companies, Data World, European Commission, Industrial Research and Innovation, http://iri.jrc.ec.europa.eu/scoreboard16.html (20.07.2018).
• EC, IRI, 2017, R&D ranking of the world top 2500 companies, Data World, European Commission, Industrial Research and Innovation, http://iri.jrc.ec.europa.eu/scoreboard17.html (20.07.2018).
• Eccles R.G., Krzus M., 2010, One Report: Integrated Reporting for a Sustainable Strategy, John Wiley & Sons, Hoboken, NJ.
• Eccles R.G., Serafeim G., 2014, Corporate and integrated reporting: A functional perspective, Working Paper 14-094, Harvard Business School.
• Eccles R.G., Serafeim G., Krzus M., 2011, Market interest in nonfinancial information, Journal of Applied Corporate Finance, vol. 23, s. 113-127.
• Edvinsson L., 1997, Developing intellectual capital at Skandia, Long Range Planning, vol. 30, no. 3, s. 320-331.
• Edvinsson L., Malone S.M., 1997, Intellectual Capital: Realizing Your Company's True Value by Finding Its Hidden Brainpower, Harper Collins Publishers, New York.
• Elkington J., 1997, Cannibals with Forks: The Triple Bottom Line of 21st Century Business, Capstone Publishing, Oxford.
• Elliott R.K., Jacobson P.D., 1994, Cost and benefits of business information disclosure, Accounting Horizons, vol. 8, no. 4, s. 80-96.
• Ellis J., Williams D., 1997, Strategia przedsiębiorstwa a analiza finansowa. Pozycja na rynku kapitałowym, Fundacja Rozwoju Rachunkowości w Polsce, Warszawa.
• Elsbach K.D., Sutton R.I., 1992, Acquiring organizational legitimacy through illegitimate actions: A marriage of institutional and impression management theories, Academy of Management Journal, vol. 35, no. 4, s. 699-738.
• Ely K., Simko P., Thomas L.G., 2003, The usefulness of biotechnology firms' drug development status in the evaluation of research and development costs, Journal of Accounting, Auditing and Finance, vol. 18, s. 163-196.
• EMA, 2011, Standard operating procedure: Sampling and testing of centrally authorised products,European Medicine Agency, http://www.ema.europa.eu/docs/en_GB/document_library/Standard_Operating_Procedure_-_SOP/2009/09/WC500003162.pdf (8.09.2017).
• EMA, 2012, Standard operating procedure: Dealing with reports of suspected defective medicinal products, European Medicine Agency, http://www.ema.europa.eu/docs/en_GB/document_library/Standard_Operating_Procedure_-_SOP/2009/09/WC500003189.pdf (8.09.2017).
• EMA, 2017a, Clinical Trial Regulation, European Medicine Agency, http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000629.jsp (25.07.2017).
• EMA, 2017b, Good Pharmacovigilance Practices, European Medicine Agency, http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000345.jsp&mid=WC0b01ac058058f32c